Perceptive Advisors’s Vaxcyte PCVX Stock Holding History

Perceptive Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-706,567	Closed	-$26.7M	–	102
2025 Q1	$26.7M	Sell	706,567 -1,011,850	-59%	-$80.9M	0.94%	30
2024 Q4	$141M	Sell	1,718,417 -309,191	-15%	-$30.7M	3.88%	7
2024 Q3	$232M	Buy	2,027,608 +165,000	+9%	+$14.9M	4.9%	5
2024 Q2	$141M	Sell	1,862,608 -70,151	-4%	-$4.78M	3.39%	7
2024 Q1	$132M	Buy	1,932,759 +844,273	+78%	+$58.5M	2.31%	10
2023 Q4	$68.4M	Sell	1,088,486 -254,265	-19%	-$13.2M	1.53%	20
2023 Q3	$68.5M	Sell	1,342,751 -271,371	-17%	-$13.4M	2.28%	12
2023 Q2	$80.6M	Buy	1,614,122 +444,122	+38%	+$21.1M	2.33%	12
2023 Q1	$43.9M	Hold	1,170,000	–	–	1.29%	22
2022 Q4	$56.1M	Buy	+1,170,000	New	+$45.9M	1.58%	21
2021 Q2	–	Sell	-850,000	Closed	-$16.8M	–	158
2021 Q1	$16.8M	Hold	850,000	–	–	0.21%	83
2020 Q4	$22.6M	Hold	850,000	–	–	0.24%	80
2020 Q3	$42M	Hold	850,000	–	–	0.61%	43
2020 Q2	$26.9M	Buy	+850,000	New	+$27.3M	0.44%	52

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Perceptive Advisors's PCVX Position: Q2 2025 in Review

Perceptive Advisors sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 706,567 shares — an estimated $26.7M sold.

Perceptive Advisors first reported a position in PCVX in Q2 2020 and held it in 14 quarters. The position peaked at $232M in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Perceptive Advisors reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Perceptive Advisors sold 706,567 Vaxcyte shares in Q2 2025, an estimated $26.7M.
Perceptive Advisors first reported a position in Vaxcyte in Q2 2020 and held it in 14 quarters.
Perceptive Advisors's Vaxcyte position peaked at $232M in Q3 2024.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.